Navigation Links
AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
Date:1/11/2011

WILMINGTON, Del. and NASHVILLE, Tenn., Jan. 11, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

Cancer is a major cause of mortality globally; accounting for 7.4 million (or 13%) of all deaths in 2004. The World Health Organization estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015, driving the critical need for novel therapies to reach patients quickly and efficiently.

Under the agreement, SCRI will collaborate with AstraZeneca to provide clinical program development expertise, clinical program design, medical oversight and trial management. The first clinical trial to be conducted under the agreement was initiated in November 2010 with the first patient enrollment into that clinical trial on November 23, 2010.  

Potential benefits to be derived from this unique collaboration include enhanced strategic clinical development in pursuit of new and more effective cancer therapies, flexibility in program design and implementation, innovation via realizing efficiencies across the collaboration, leveraging the strengths of the innovative collaboration, and rapid patient enrollment to clinical trials through the access of a large network of cancer patients.  

Andrew Hughes, Vice President, Oncology Clinical Innovative Medicines, said: "AstraZeneca has a long history of discovering and developing cancer therapeutics that have made a real difference to cancer patients. For many years we have enjoyed an excellent working relationship with SCRI and this is an exciting next step in our relationship that continues to foster collaboration and innovation in advan
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
2. Rigel Earns Milestone Payments From AstraZeneca
3. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
4. AstraZeneca Outlines Principles for Product-Related Online Communications
5. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
6. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
7. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
8. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
9. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
10. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
11. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... 10, 2014 Robert Harman, DVM, Founder and ... is proud to announce the relaunch of his highly informative ... new series called “ What are Stem Cells ?” ... and straightforward foundation in the basics of stem cell therapy ... the right type of treatment when considering regenerative medicine. , ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... a researcher, please contact the Communications and External Relations staff ... information on ORNL and its research and development activities, please ... a general media-related question or comment, you can send it ... Intelligent intelligence . . . In combat situations, ...
... full day with the announcement of the 2010 Kavli ... by Harold Varmus, co-chair of President Obama,s Council of ... live simulcast of the announcement of the laureates by ... Norway. A panel discussion follows, moderated by Elizabeth ...
... Calif. , May 21 Abviva, Inc. (Pink Sheets: ... breast cancer related applications of Mammastatin, today provided further details about ... , , , ... previously announced that the Japanese Patent Office issued two patents on ...
Cached Biology Technology:Story tips from the Department of Energy's Oak Ridge National Laboratory May 2010 2Story tips from the Department of Energy's Oak Ridge National Laboratory May 2010 3Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology 2Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology 3
(Date:7/11/2014)... team of researchers from The Chinese University of Hong ... of wild soybean linked to salt tolerance, with implication ... soil. This study published online in Nature Communications ... information for crop improvement. , Soybean is an important ... selection, cultivated soybeans have less genetic diversities than their ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... , This release is available in French ... there has been a huge amount of groundwater pollution worldwide, ... water supply," says Barbara Sherwood Lollar, Canada Research Chair in ... University of Toronto. Sherwood Lollar is taking part ...
... generation of sensors with applications ranging from medical ... Liu looks to biology. Liu, professor of mechanical ... University,s McCormick School of Engineering and Applied Science, is ... and flow sensors areas that currently lack good ...
... The arrival of affordable, high throughput DNA sequencing, coupled ... major advances in the field of molecular plant breeding. ... are able to investigate genome-wide variations in DNA sequences ... traits controlled by many genes, such as hybrid vigor. ...
Cached Biology News:Water, water, everywhere… but is it safe to drink? 2Turning to nature for inspiration 2
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... transporter 2 (APT2) (Peptide ... PSF2) (Peptide supply factor ... involved in antigen processing ... Antigen: Recombinant ...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Biology Products: